Dr. Chan Yau Ki Wilson - Paediatrics
Specialist in Paediatrics
Highlights
- MCHK RegisteredVerified
- Specialist in PaediatricsBachelor of Medicine and Bachelor of Surgery (MBBS) · Hong Kong College of Paediatricians · Medical degree 2010
- InsuranceBeing compiled｜See details
About
Dr. Chan Yau Ki Wilson is a registered Paediatrics specialist in Hong Kong.
Education
Specialist in Paediatrics
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)2010
Hong Kong Academy of Medicine fellowships
- FHKCPaedFellow, Hong Kong College of Paediatricians
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Chan Yau Ki Wilson? Claim page and update insurance →
FAQ
Is Dr. Chan Yau Ki Wilson any good?
Dr. Chan Yau Ki Wilson is a registered Paediatrics specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Chan Yau Ki Wilson do?
Dr. Chan Yau Ki Wilson practises in Paediatrics.
Are you Dr. Chan Yau Ki Wilson? Claim this page to update and manage.
ClaimResearch and publications
15 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Generation of CCR4/CD7 Bispecific CAR-T Cells Resistant to Fratricide and Exhaustion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
- Chimeric antigen receptor-based cellular therapy for T-cell malignancies.Critical reviews in oncology/hematology · 2026
- Memory T Cell Donor Lymphocyte Infusion as a Treatment for Viral Infection After Pediatric Haploidentical Hematopoietic Stem Cell Transplant.Transplantation and cellular therapy · 2026
- Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma.Cytotherapy · 2026
- HLA vaccine effect in double cord blood transplant: a Chinese cohort.Blood advances · 2025
- A Modified Three-Step Haploidentical Transplantation With TCRαβ/CD62L Depletion for Epstein-Barr Virus Hemophagocytic Lymphohistiocytosis and Natural Killer-Cell Lymphoproliferative Disease.Pediatric blood & cancer · 2025
- Autologous hematopoietic stem cell transplantation followed by quadruple immunotherapy with dinutuximab beta, sargramostim, aldesleukin, and spironolactone for relapsed metastatic retinoblastoma.Pediatric blood & cancer · 2024
- High infection rates and risk-adapted prevention strategies in contemporary pediatric allogeneic hematopoietic stem cell transplantation.Pediatric discovery · 2024
- Blinatumomab with donor lymphocyte infusions post haploidentical hematopoietic stem cell transplantation as salvage therapy for relapsed refractory acute lymphoblastic leukemia post chimeric antigen receptor T-cell therapy.Pediatric blood & cancer · 2023
- SARS-CoV-2 infection in children undergoing oncologic treatment in Hong Kong: A population-based cohort during the Omicron wave.Pediatric blood & cancer · 2023
- Successful haploidentical hematopoietic stem cell transplantation (HSCT) and durable engraftment by repeated donor lymphocyte infusions for a Chinese patient with transfusion-dependent hemoglobin (Hb) Hammersmith and massive splenomegaly.Pediatric transplantation · 2022
- Epidemiology and outcomes of pediatric transplant-associated thrombotic microangiopathy in Hong Kong.Pediatric transplantation · 2022
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer